In AML, DNMT3a plays a crucial role since more than 20% of patients exhibit DNMT3A mutation (105), conferring a global hypomethylation of DNA and predisposition to developing hematological diseases (106). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.